Health Care/Hospital

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regional ESG Top-Rated Company for five consecutive years * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading ...

2025-07-16 18:00 1835

JETRO and METI Hold First-ever "Global Healthcare Challenge," Featuring International Symposium in Healthcare Sector and Pitch Competition among World's Startups

- AI Medical Service Inc. from Japan Wins Gold Prize - TOKYO, July 16, 2025 /PRNewswire/ -- During the "Health and Well-being" theme week at the Expo 2025 Osaka, Kansai, the Japan External Trade Organization (JETRO) andJapan's Ministry of Economy, Trade and Industry (METI) jointly hosted an inte...

2025-07-16 14:00 1605

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U...

2025-07-16 10:32 1820

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastati...

2025-07-16 09:47 1996

Avio Health Launches AI Platform to Turn Disconnected Health Data into Preventive Intelligence

How Avio Health Is Rewiring Medicine for the Age of AI PALO ALTO, Calif. , July 15, 2025 /PRNewswire/ -- Today, Avio Health announced the launch of its proprietary clinical AI platform, which is designed to unify health data and support the shift toward preventative, personalized care. By integr...

2025-07-15 21:41 1438

Introducing the VARON VP-8G: A Smarter, Lighter Portable Oxygen Concentrator Built for Life on the Move

NEW YORK, July 15, 2025 /PRNewswire/ -- For those who need reliable oxygen support without compromising mobility,VARON proudly introduces the VP-8G portable oxygen concentrator

2025-07-15 20:25 1178

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Nietham...

2025-07-15 19:30 1517

Youthful Narrative Bridges Traditional Chinese Medicine to Global Audience

LIAOCHENG, China, July 15, 2025 /PRNewswire/ -- Amidst global challenges in chronic disease prevention and health management, Traditional Chinese Medicine (TCM)'s core principles of "preventive treatment of disease" (zhi wei bing, 治未病) and "harmony between humanity and nature" (tian ren he yi, 天人...

2025-07-15 16:45 1480

Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors

 TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and  RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...

2025-07-15 14:00 1616

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, onc...

2025-07-15 07:00 1973

Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the s...

2025-07-15 04:05 1822

Health In Tech to Announce Second Quarter 2025 Financial Results on July 21, 2025

STUART, Fla., July 14, 2025 /PRNewswire/ -- Health In Tech (NASDAQ: HIT), an Insurtech platform company backed by third-party AI technology, today announced that it will release financial results for the quarter endedJune 30, 2025, following the close of market onMonday, July 21, 2025. Health In ...

2025-07-15 01:00 2702

Zepp Health Corporation to Report Second Quarter 2025 Financial Results on August 3, 2025

Earnings Call Scheduled for 9:30 p.m. ET on August 3, 2025 MILPITAS, Calif., July 14, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its second quarter 2025 ...

2025-07-14 19:00 2353

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...

2025-07-14 15:38 1394

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP34...

2025-07-14 08:00 1540

Angel Yeast Unveils 2024 Sustainability Report, Showcasing Commitment to Green Practices and Innovation

SHANGHAI, July 11, 2025 /PRNewswire/ -- Angel Yeast (600298.SH) recently released its 2024 Sustainability (ESG) Report, providing in-depth insights into the company's thoughts and actions towards sustainable development management. The report highlights significant eff...

2025-07-11 15:18 2236

LG Debuts Next-Generation Precision Medical AI

Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ -- LG AI Research announced on July 9 the official launch of 'EXAONE Path 2.0', its next-generation precision medical AI model. Followin...

2025-07-10 20:54 2289

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics,...

2025-07-10 19:00 1643

Tokyo Lifestyle Co., Ltd. Reports Fiscal Year 2025 Financial Results

TOKYO, July 10, 2025 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in ...

2025-07-10 18:00 3656

Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells

PALO ALTO, Calif., July 10, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/ ), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jo...

2025-07-10 18:00 2802
1 ... 26272829303132 ... 308